Lipocalin-2 is increased in progressive multiple sclerosis and inhibits remyelination

Al Nimer, F. et al. (2016) Lipocalin-2 is increased in progressive multiple sclerosis and inhibits remyelination. Neurology: Neuroimmunology and Neuroinflammation, 3(1), e191. (doi: 10.1212/NXI.0000000000000191) (PMID:26770997) (PMCID:PMC4708925)

[img]
Preview
Text
190785.pdf - Published Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

965kB

Abstract

Objective: We aimed to examine the regulation of lipocalin-2 (LCN2) in multiple sclerosis (MS) and its potential functional relevance with regard to myelination and neurodegeneration. Methods: We determined LCN2 levels in 3 different studies: (1) in CSF and plasma from a case-control study comparing patients with MS (n = 147) with controls (n = 50) and patients with relapsing-remitting MS (n = 75) with patients with progressive MS (n = 72); (2) in CSF and brain tissue microdialysates from a case series of 7 patients with progressive MS; and (3) in CSF at baseline and 60 weeks after natalizumab treatment in a cohort study of 17 patients with progressive MS. Correlation to neurofilament light, a marker of neuroaxonal injury, was tested. The effect of LCN2 on myelination and neurodegeneration was studied in a rat in vitro neuroglial cell coculture model. Results: Intrathecal production of LCN2 was increased predominantly in patients with progressive MS (p < 0.005 vs relapsing-remitting MS) and displayed a positive correlation to neurofilament light (p = 0.005). Levels of LCN2 in brain microdialysates were severalfold higher than in the CSF, suggesting local production in progressive MS. Treatment with natalizumab in progressive MS reduced LCN2 levels an average of 13% (p < 0.0001). LCN2 was found to inhibit remyelination in a dose-dependent manner in vitro. Conclusions: LCN2 production is predominantly increased in progressive MS. Although this moderate increase does not support the use of LCN2 as a biomarker, the correlation to neurofilament light and the inhibitory effect on remyelination suggest that LCN2 might contribute to neurodegeneration through myelination-dependent pathways.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Elliott, Dr Christina and Linington, Professor Christopher
Authors: Al Nimer, F., Elliott, C., Bergman, J., Khademi, M., Dring, A. M., Aeinehband, S., Bergenheim, T., Romme Christensen, J., Sellebjerg, F., Svenningsson, A., Linington, C., Olsson, T., and Piehl, F.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cardiovascular and Medical Sciences
College of Medical Veterinary and Life Sciences > Institute of Infection Immunity and Inflammation
Journal Name:Neurology: Neuroimmunology and Neuroinflammation
Publisher:Wolters Kluwer Health/LWW
ISSN:2332-7812
ISSN (Online):2332-7812
Published Online:07 January 2016
Copyright Holders:Copyright © 2016 American Academy of Neurology
First Published:First published in Neurology: Neuroimmunology and Neuroinflammation 3(1):e191
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record